UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Poorly-differentiated cancer from an unknown primary site

Authors
John D Hainsworth, MD
F Anthony Greco, MD
Section Editor
George P Canellos, MD
Deputy Editor
Sadhna R Vora, MD

INTRODUCTION

Cancer of unknown primary site (CUP) is a relatively common clinical entity, accounting for approximately 4 to 5 percent of all invasive cancer diagnoses [1]. Within this category, tumors from many primary sites with varying biology are represented. Most cancers of unknown primary site are adenocarcinomas and can be recognized by routine histologic examination. However, 20 to 25 percent of CUPs are poorly differentiated and cannot be precisely characterized by histologic examination. About 80 percent of these poorly-differentiated tumors have features of carcinoma, and are termed “poorly-differentiated carcinoma” after initial pathologic examination. In the remainder, histologic examination results in the diagnosis of “poorly-differentiated neoplasm,” signifying the inability to distinguish between carcinoma, melanoma, lymphoma, sarcoma, or germ cell tumor.

As accurate a diagnosis as possible is essential since the therapy for various tumors can be quite different and may be curative in some patients. The diagnostic approach to poorly-differentiated cancers of unknown primary site will be reviewed here, along with the prognostic and therapeutic implications.

Other relevant topics include:

(See "Overview of the classification and management of cancers of unknown primary site".)

(See "Adenocarcinoma of unknown primary site".)

             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Dec 09 00:00:00 GMT+00:00 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Greco FA, Hainsworth JD. Introduction: unknown primary cancer. Semin Oncol 2009; 36:6.
  2. Møller AK, Loft A, Berthelsen AK, et al. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist 2012; 17:1146.
  3. Hainsworth JD, Wright EP, Gray GF Jr, Greco FA. Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy. J Clin Oncol 1987; 5:1275.
  4. Battifora H, Trowbridge IS. A monoclonal antibody useful for the differential diagnosis between malignant lymphoma and nonhematopoietic neoplasms. Cancer 1983; 51:816.
  5. Gabbiani G, Kapanci Y, Barazzone P, Franke WW. Immunochemical identification of intermediate-sized filaments in human neoplastic cells. A diagnostic aid for the surgical pathologist. Am J Pathol 1981; 104:206.
  6. Nagle RB, McDaniel KM, Clark VA, Payne CM. The use of antikeratin antibodies in the diagnosis of human neoplasms. Am J Clin Pathol 1983; 79:458.
  7. Schlegel R, Banks-Schlegel S, McLeod JA, Pinkus GS. Immunoperoxidase localization of keratin in human neoplasms: a preliminary survey. Am J Pathol 1980; 101:41.
  8. Warnke RA, Gatter KC, Falini B, et al. Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. N Engl J Med 1983; 309:1275.
  9. Michels S, Swanson PE, Frizzera G, Wick MR. Immunostaining for leukocyte common antigen using an amplified avidin-biotin-peroxidase complex method and paraffin sections. A study of 735 hematopoietic and nonhematopoietic human neoplasms. Arch Pathol Lab Med 1987; 111:1035.
  10. Denk H, Krepler R, Artlieb U, et al. Proteins of intermediate filaments. An immunohistochemical and biochemical approach to the classification of soft tissue tumors. Am J Pathol 1983; 110:193.
  11. Osborn M, Weber K. Tumor diagnosis by intermediate filament typing: a novel tool for surgical pathology. Lab Invest 1983; 48:372.
  12. Ramaekers FC, Vroom TM, Moesker O, et al. The use of antibodies to intermediate filament proteins in the differential diagnosis of lymphoma versus metastatic carcinoma. Histochem J 1985; 17:57.
  13. Kahn HJ, Marks A, Thom H, Baumal R. Role of antibody to S100 protein in diagnostic pathology. Am J Clin Pathol 1983; 79:341.
  14. Mottolese M, Venturo I, Benevolo M, et al. Immunocytochemical diagnosis of amelanotic metastatic melanoma using monoclonal antibodies HMB-45 and Ep1-3. Melanoma Res 1994; 4:53.
  15. Ohsawa M, Naka N, Tomita Y, et al. Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases. Cancer 1995; 75:2867.
  16. Leader M, Collins M, Patel J, Henry K. Staining for factor VIII related antigen and Ulex europaeus agglutinin I (UEA-I) in 230 tumours. An assessment of their specificity for angiosarcoma and Kaposi's sarcoma. Histopathology 1986; 10:1153.
  17. Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1.
  18. Park SY, Kim BH, Kim JH, et al. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 2007; 131:1561.
  19. Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol 2010; 18:3.
  20. Oien KA, Dennis JL. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Ann Oncol 2012; 23 Suppl 10:x271.
  21. O'Connor DT, Burton D, Deftos LJ. Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues. J Clin Endocrinol Metab 1983; 57:1084.
  22. Allhoff EP, Proppe KH, Chapman CM, et al. Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer. J Urol 1983; 129:315.
  23. Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer 2004; 101:2006.
  24. Bar-Eli M, Abbruzzese JL, Lee-Jackson D, Frost P. p53 gene mutation spectrum in human unknown primary tumors. Anticancer Res 1993; 13:1619.
  25. Briasoulis E, Tsokos M, Fountzilas G, et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. Anticancer Res 1998; 18:1907.
  26. Pavlidis N, Briassoulis E, Bai M, et al. Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res 1995; 15:2563.
  27. Alsabeh R, Wilson CS, Ahn CW, et al. Expression of bcl-2 by breast cancer: a possible diagnostic application. Mod Pathol 1996; 9:439.
  28. Greco FA, Spigel DR, Yardley DA, et al. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 2010; 15:500.
  29. Greco FA, Lennington WJ, Spigel DR, Hainsworth JD. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst 2013; 105:782.
  30. Greco FA, Spigel DR, and Hainsworth JD. Molecular tumor profiling of poorly differentiated neoplasms of unknown primary site (abstract). J Clin Oncol 31, 2013 (suppl; abstr 11080)
  31. Hammar SP. Metastatic adenocarcinoma of unknown primary origin. Hum Pathol 1998; 29:1393.
  32. Arnold A, Cossman J, Bakhshi A, et al. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med 1983; 309:1593.
  33. Cleary ML, Chao J, Warnke R, Sklar J. Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc Natl Acad Sci U S A 1984; 81:593.
  34. Lossos IS, Okada CY, Tibshirani R, et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 2000; 95:1797.
  35. Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988; 32:229.
  36. Whang-Peng J, Triche TJ, Knutsen T, et al. Chromosome translocation in peripheral neuroepithelioma. N Engl J Med 1984; 311:584.
  37. Bosl GJ, Ilson DH, Rodriguez E, et al. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 1994; 86:349.
  38. Summersgill B, Goker H, Osin P, et al. Establishing germ cell origin of undifferentiated tumors by identifying gain of 12p material using comparative genomic hybridization analysis of paraffin-embedded samples. Diagn Mol Pathol 1998; 7:260.
  39. Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012; 18:5773.
  40. Horning SJ, Carrier EK, Rouse RV, et al. Lymphomas presenting as histologically unclassified neoplasms: characteristics and response to treatment. J Clin Oncol 1989; 7:1281.
  41. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004; 100:1257.
  42. Greco FA, Burris HA 3rd, Erland JB, et al. Carcinoma of unknown primary site. Cancer 2000; 89:2655.
  43. Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000; 11:211.
  44. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000; 18:3101.
  45. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10:912.
  46. Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 2013; 31:217.
  47. Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003; 21:3479.
  48. Hainsworth JD, Erland JB, Kalman LA, et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 1997; 15:2385.
  49. Greco FA, Burris HA 3rd, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002; 20:1651.
  50. Greco FA, Rodriguez GI, Shaffer DW, et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist 2004; 9:644.
  51. French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012; 7:247.
  52. Haack H, Johnson LA, Fry CJ, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol 2009; 33:984.